HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
E 4010
structure in first source
Also Known As:
4-(3-chloro-4-methoxybenzyl)amino-1(4-hydroxypiperidino)-6-phthalazinecarbonitrile monohydrochlodride; E-4010; E4010
Networked:
2
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Nitriles: 227
E 4010: 2
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Piperidines: 17
E 4010: 2
Related Diseases
1.
Pulmonary Hypertension
08/01/1999 - "
These results suggest that E4010 will be useful for the treatment of pulmonary hypertension.
"
01/01/1999 - "
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
"
08/01/1999 - "
We investigated the effects of long-term treatment with a selective phosphodiesterase 5 inhibitor E4010, 4-(3-chloro-4methoxybenzyl)amino-1-(4-hydroxypiperidino)-6-phth alazin ecarbonitrile monohydrochloride, on the survival rate of rats with pulmonary hypertension induced by monocrotaline (MCT).
"
01/01/1999 - "
The purpose of this study was to determine whether E-4010, a newly synthesized potent and selective orally active phosphodiesterase (PDE) 5 inhibitor, would prevent the development of chronic hypoxia-induced pulmonary hypertension in rats.
"
2.
Hypoxia (Hypoxemia)
01/01/1999 - "
These results suggest that long-term oral treatment with E-4010 reduced the increase in PAP, right ventricular hypertrophy, and pulmonary arterial remodeling induced by exposure to chronic hypoxia, probably through increasing cGMP levels in the pulmonary vascular smooth muscle.
"
01/01/1999 - "
In rats that received food containing 0.01 or 0.1% E-4010 during the 3-wk exposure to hypoxia, mean PAP was significantly decreased (mean PAP 24.0 +/- 0.9, 16.2 +/- 0.8, and 12.8 +/- 0.5 mmHg in rats treated with 0, 0.01, and 0.1% E-4010-containing food, respectively), whereas mean systemic arterial pressure was unchanged and cardiac output was slightly increased compared with chronically hypoxic control rats.
"
01/01/1999 - "
The purpose of this study was to determine whether E-4010, a newly synthesized potent and selective orally active phosphodiesterase (PDE) 5 inhibitor, would prevent the development of chronic hypoxia-induced pulmonary hypertension in rats.
"
3.
Right Ventricular Hypertrophy
01/01/1999 - "
These results suggest that long-term oral treatment with E-4010 reduced the increase in PAP, right ventricular hypertrophy, and pulmonary arterial remodeling induced by exposure to chronic hypoxia, probably through increasing cGMP levels in the pulmonary vascular smooth muscle.
"
08/01/1999 - "
In E4010 0.1%-treated rats (n = 27), the right ventricular hypertrophy was suppressed, and the increase in plasma cGMP level was amplified compared with MCT without any effects on plasma ANP, BNP, and cyclic AMP levels.
"
4.
Vascular Remodeling
01/01/1999 - "
These results suggest that long-term oral treatment with E-4010 reduced the increase in PAP, right ventricular hypertrophy, and pulmonary arterial remodeling induced by exposure to chronic hypoxia, probably through increasing cGMP levels in the pulmonary vascular smooth muscle.
"
Related Drugs and Biologics
1.
Phosphodiesterase 5 Inhibitors
2.
Phosphoric Diester Hydrolases (Phosphodiesterases)
3.
E 4010
4.
Monocrotaline
5.
Atrial Natriuretic Factor (ANF)
6.
Cyclic AMP (AMP, Cyclic)